VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | ZUMA-1 & SCHOLAR-1: comparison of outcomes in refractory DLBCL

Christian Gisselbrecht, MD, Saint Louis Hospital, Paris, France, outlines the comparison of 2-year outcomes in ZUMA-1 (NCT02348216) and SCHOLAR-1 in patients with refractory diffuse large B-cell lymphoma (DLBCL) treated with axicabtagene ciloleucel. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Transcript (edited for clarity)

Everybody knows and it was during this meeting, roughly the same for all the CAR-T cell. Because it was that you get a quite high response rate in these relapsed/refractory patient. And that with CAR-T cell, you can get as much as a 80% response rate with half of them in complete remission. So, how long does it stay? ZUMA-1 were the first study. We have only now three years’ followup, and we know that it’s around 50%...

Everybody knows and it was during this meeting, roughly the same for all the CAR-T cell. Because it was that you get a quite high response rate in these relapsed/refractory patient. And that with CAR-T cell, you can get as much as a 80% response rate with half of them in complete remission. So, how long does it stay? ZUMA-1 were the first study. We have only now three years’ followup, and we know that it’s around 50%. But everybody can understand that there is a selection of these patient in many way, and they are maybe not exactly the same than the one we are treating with autologous stem cell transplantation.

So what we did was to try to compare the two population, 101 from the ZUMA-1 and 487 from the combined LY.12 and the CORAL study. And we did two type of analysis. One which is under publication, what we call a propensity score and the other was a standardized approach. And with these two method, we can in some way compare that it’s not really matching. Because it’s impossible to get the same population, but we can compare the different prognostic factor and the main events between the ZUMA-1 and the SCHOLAR-1 patient.

And what was very clear is that you will confirm that there is a huge difference in response rate, of course. And after the longer follow-up, after two years we have a very huge difference in favor of CAR-T cell. The overall survival is close to 50%, where it is only 20% or less for the chemotherapy arm with or without stem cell transplantation. So now what we need is to collect more and more of these data in the long term, to see if we are really curing these patient with these sort of fantastic technology.

 

Read more...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter